Insulet Corp to Present at Upcoming Investor Conferences Amidst Diabetes Management Focus

Insulet Corp will present at several investor conferences in September 2025, focusing on its Omnipod technology for diabetes management. The company's participation in these conferences is seen as a strategic move to engage with stakeholders and maintain transparency. However, the press release lacks specific financial data or updates on new product developments. Insulet's emphasis on innovation and leadership in the tubeless insulin pump market are positive indicators of its growth potential.

Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has announced its participation in several upcoming investor conferences in September 2025. The company's engagement with stakeholders is seen as a strategic move to maintain transparency and update investors on its progress. However, the press release lacks specific financial data or updates on new product developments.

Insulet will present at the following conferences:
- Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m.
- Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m.
- Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York City on September 24 at 9:40 a.m.

The live audio webcast and replay of the presentations will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.

About Insulet Corporation:
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas [1][2].

Insulet's emphasis on innovation and leadership in the tubeless insulin pump market are positive indicators of its growth potential. The company's recent share buyback and upgraded revenue guidance further underscore its confidence in product demand. However, investors should remain aware of the concentration risk around the Omnipod platform, where any disruption or competitor advance could have an outsized impact [3].

References:
[1] https://www.morningstar.com/news/business-wire/20250819765999/insulet-to-participate-in-upcoming-investor-conferences
[2] https://www.biospace.com/press-releases/insulet-to-participate-in-upcoming-september-2025-investor-conferences
[3] https://simplywall.st/stocks/us/healthcare/nasdaq-podd/insulet/news/insulets-podd-aggressive-revenue-guidance-and-buyback-might